New Formulation of FDA-Approved Drug Shows Encouraging Results for Treating a Common Itch Condition in Phase 2 Clinical Trial.

Press/Media

Period	9 Feb 2023

Media coverage

Title	New Formulation of FDA-Approved Drug Shows Encouraging Results for Treating a Common Itch Condition in Phase 2 Clinical Trial.
Media name/outlet	PRWeb Newswire
Country/Territory	United States
Date	9/02/23
URL	ct.moreover.com/?a=49975391765&p=1gw&v=1&x=VMg9B7ZKM43LUFdvkUKiJg
Persons	Mark Lebwohl, Brian Kim